A Prospective, Double-Blind, Randomized Clinical Trial Comparing Subacromial Injection of Betamethasone and Xylocaine to Xylocaine alone in Chronic Rotator Cuff Tendinosis
| Autor: | Sharon Griffin, Dianne Jackowski, Alexandra Kirkley, Christine M. Alvarez, Robert Litchfield |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
medicine.medical_specialty
medicine.drug_class Tendinosis Physical Therapy Sports Therapy and Rehabilitation Injections Intralesional Betamethasone Rotator Cuff Injuries law.invention Rotator Cuff 03 medical and health sciences 0302 clinical medicine Randomized controlled trial law medicine Humans Orthopedics and Sports Medicine Rotator cuff Prospective Studies Anesthetics Local Range of Motion Articular Glucocorticoids Pain Measurement Rupture 030222 orthopedics Shoulder Joint business.industry Rotator cuff injury Lidocaine 030229 sport sciences medicine.disease Surgery Clinical trial Treatment Outcome medicine.anatomical_structure Chronic Disease Tendinopathy Cuff Quality of Life Corticosteroid business medicine.drug |
| Zdroj: | The American Journal of Sports Medicine. 33:255-262 |
| ISSN: | 1552-3365 0363-5465 |
| DOI: | 10.1177/0363546504267345 |
| Popis: | Background Rotator cuff tendinosis is a common problem with significant health and economic effects. Nonoperative management includes the widespread use of subacromial steroid injections despite the lack of evidence of its efficacy. Hypothesis A subacromial injection of betamethasone will be more effective than xylocaine alone in improving the quality of life, impingement sign, and range of motion in patients who have chronic rotator cuff tendinosis or partial rotator cuff tears. Study Design Randomized controlled clinical trial; Level of evidence, 1. Methods Patients with rotator cuff tendinosis or partial cuff tear with symptoms longer than 6 months, with failure of 6 weeks of physical therapy and 2 weeks of nonsteroidal anti-inflammatory drugs, who were older than 30 years of age, and who showed > 50% improvement with the Neer impingement test were stratified for Workplace Safety and Insurance Board status and previous injection. Outcome measures—the Western Ontario Rotator Cuff Index; American Shoulder and Elbow Surgeons standardized form; Disabilities of the Arm, Shoulder and Hand; active forward elevation; active internal rotation; active external rotation; and the Neer impingement sign—were assessed at 2, 6, 12, and 24 weeks after injection. The injection into the subacromial space contained either 5 mL of 2% xylocaine alone or 4 mL of 2% xylocaine and 1 mL (6 mg) of betamethasone in an opaque syringe. Results In 58 patients (betamethasone group, n = 30; xylocaine group, n = 28), the authors found no statistically significant difference between the 2 treatment groups for all outcomes and time intervals. The scores for the Western Ontario Rotator Cuff Index at 3 months were xylocaine = 45.4% ± 13% and betamethasone = 56.3% ± 17% (P=. 13). At 6 months, the scores were xylocaine = 51% ± 32% and betamethasone = 59% ± 26% (P=. 38). All other outcomes showed similar values. As well, similar results were found for 2 and 6 weeks after injection. Both groups showed improvement from baseline in all outcomes. Conclusions With the numbers available for this study, the authors found betamethasone to be no more effective in improving the quality of life, range of motion, or impingement sign than xylocaine alone in patients with chronic rotator cuff tendinosis for all follow-up time intervals evaluated. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|